- Home
- ZH vs DBVT Comparison
ZH vs DBVT Comparison
Compare ZH & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZH
- DBVT
- Stock Information
- Founded
- ZH 2011
- DBVT 2002
- Country
- ZH China
- DBVT France
- Employees
- ZH N/A
- DBVT N/A
- Industry
- ZH Business Services
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZH Consumer Discretionary
- DBVT Health Care
- Exchange
- ZH Nasdaq
- DBVT Nasdaq
- Market Cap
- ZH 352.6M
- DBVT 289.8M
- IPO Year
- ZH 2021
- DBVT N/A
- Fundamental
- Price
- ZH $4.51
- DBVT $9.46
- Analyst Decision
- ZH Strong Buy
- DBVT Buy
- Analyst Count
- ZH 1
- DBVT 4
- Target Price
- ZH $4.70
- DBVT $14.81
- AVG Volume (30 Days)
- ZH 309.6K
- DBVT 20.0K
- Earning Date
- ZH 08-21-2025
- DBVT 08-05-2025
- Dividend Yield
- ZH N/A
- DBVT N/A
- EPS Growth
- ZH N/A
- DBVT N/A
- EPS
- ZH N/A
- DBVT N/A
- Revenue
- ZH $464,095,225.00
- DBVT $3,497,000.00
- Revenue This Year
- ZH N/A
- DBVT $1,700.53
- Revenue Next Year
- ZH $7.46
- DBVT $535.67
- P/E Ratio
- ZH N/A
- DBVT N/A
- Revenue Growth
- ZH N/A
- DBVT N/A
- 52 Week Low
- ZH $3.01
- DBVT $2.21
- 52 Week High
- ZH $6.32
- DBVT $12.78
- Technical
- Relative Strength Index (RSI)
- ZH 52.60
- DBVT 46.80
- Support Level
- ZH $4.58
- DBVT $9.13
- Resistance Level
- ZH $4.95
- DBVT $10.16
- Average True Range (ATR)
- ZH 0.19
- DBVT 0.56
- MACD
- ZH -0.02
- DBVT -0.14
- Stochastic Oscillator
- ZH 10.20
- DBVT 11.96
About ZH Zhihu Inc. (every two of each representing one ordinary share)
Zhihu Inc is predominantly engaged in the operation of one online content community and monetizes through paid membership services, advertising services, content-commerce solutions services, and vocational training in China. It generates revenues from Advertising services, Paid membership services, Content-commerce solutions, and Others. It derives all its revenues within China.
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.